209959-26-2

Basic information

• Product Name: tert-butyl 4-(4-aminophenyl)-1H-pyrazole-1-carboxylate
• Synonyms: tert-butyl 4-(4-aminophenyl)-1H-pyrazole-1-carboxylate
• CAS NO: 209959-26-2
• Molecular Weight: 259.308
• Mol File: 209959-26-2.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-aminophenyl)-1H-pyrazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-aminophenyl)-1H-pyrazole-1-carboxylate(209959-26-2)
• EPA Substance Registry System: tert-butyl 4-(4-aminophenyl)-1H-pyrazole-1-carboxylate(209959-26-2)

Safety Data

• Hazardous Substances Data: 209959-26-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 114474-26-9 4-(4-nitrophenyl)-1H-pyrazole 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 552846-17-0 tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate 
• 586-78-7 para-nitrophenyl bromide 
• 209959-25-1 tert-butyl 4-(4-nitrophenyl)-1H-pyrazole-1-carboxylate 

Downstream Products

• 1610874-68-4 N-(4-(1H-pyrazol-4-yl)phenyl)-3-(2-chlorophenyl)propanamide 
• 1610875-33-6 tert-butyl 4-(4-(3-(2-chlorophenyl)propanamido)phenyl)-1H-pyrazole-1-carboxylate 

Relevant articles and documents

ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

The invention relates to a ROCK inhibitor represented by formula (I), its preparation method and its use. The ROCK inhibitor has excellent ROCK inhibition activity, in particular good selective inhibition on ROCK2 kinase, has good safety and metabolic stability, and has high bioavailability. The process of preparing the ROCK inhibitor is simple, and the ROCK inhibitor is easy to purify, and therefore offers good prospects for application.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).